Gallitto, M., Zhang, X., De Los Santos, G., Wei, H.-J., Fernández, E. C., Duan, S., Sedor, G., Yoh, N., Kokossis, D., Angel, J. C., Wang, Y.-F., White, E., Kinslow, C. J., Berg, X., Tomassoni, L., Zandkarimi, F., Chio, I. I. C., Canoll, P., Bruce, J. N., … Wu, C.-C. (2024). Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae215

Kim, K.-S., Habashy, K., Gould, A., Zhao, J., Najem, H., Amidei, C., Saganty, R., Arrieta, V. A., Dmello, C., Chen, L., Zhang, D. Y., Castro, B., Billingham, L., Levey, D., Huber, O., Marques, M., Savitsky, D. A., Morin, B. M., Muzzio, M., … Sonabend, A. M. (2024). Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro-Oncology, 26(11), 2044–2060. https://doi.org/10.1093/neuonc/noae135

Kinslow, C. J., Roy, S., Iwamoto, F. M., Brown, P. D., DeStephano, D. M., Canoll, P. D., Qureshi, S. S., Gallito, M., Sisti, M. B., Bruce, J. N., Horowitz, D. P., Kachnic, L. A., Neugut, A. I., Yu, J. B., Mehta, M. P., Cheng, S. K., & Wang, T. J. C. (2024). The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae102

Gallitto, M., De Santos, G. L., Wei, H.-J., Zhang, X., Zhang, Z., & Wu, C.-C. (2024). DIPG-41. CONVECTION ENHANCED DELIVERY-MEDIATED RADIOSENSITIZATION FOR DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.094

Szalontay, L., Fino, J., Berg, X., Lipina, J., Gallitto, M., De Santos, G. L., Yoh, N., Gartrell, R., Pavisic, J., Garvin, J., Lignelli, A., Gomes, W., Feldstein, N., Konofagou, E. E., Zacharoulis, S., & Wu, C.-C. (2024). DIPG-93. OVERALL EXPERIENCE OF TWO PHASE I CLINICAL TRIALS WITH FOCUSED ULTRASOUND-MEDIATED BLOOD BRAIN BARRIER OPENING IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH PROGRESSIVE DIPG/DMG USING A NEURONAVIGATION-BASED DEVICE. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.146

Larson, J. D., Finlay, D., Murad, R., Lo, Y. Y., Zhao, M., Manuvel, A. M. K., Kumar, S. A., Pass, I., Handley, C., Wechsler-Reya, R. J., Taylor, M. D., Vuori, K., Chavez, L., & Jackson, M. (2024). EPEN-26. DRUG SCREENING IN PATIENT-DERIVED MODELS OF POSTERIOR FOSSA A EPENDYMOMA REVEALS NOVEL PHARMACOLOGICAL VULNERABILITIES. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.228

Katsushima, K., Joshi, K., Yuan, M., Batish, M., Stapleton, S., Jallo, G., Seal, S., Taylor, M. D., Wechsler-Reya, R. J., Eberhart, C. G., & Perera, R. J. (2024). MDB-01. A POSITIVE FEEDBACK LOOP BETWEENLNC-HLX-2-7, HLX, AND MYC STRONGLY PROMOTES GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.450

Infante, P., Conenna, M., Adabbo, G., Bufalieri, F., Bottero, M., Severini, L. L., Bartolini, F., & Marcotullio, L. D. (2024). MDB-28. THE CYTOSKELETON REGULATORS FORMINS CONTROL THE SHH PATHWAY AND ARE INVOLVED IN MEDULLOBLASTOMA TUMORIGENESIS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.477

Tsetlina, V., Cassidy, D., Tenaglia, A. L., Levin, J., Tsao, E., & Ibanez, K. (2024). QOL-12. LESSONS LEARNED FROM LONGITUDINAL CARE IN POSTERIOR FOSSA SYNDROME. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.600

Minns, H. E., Padilla, O., Wei, H.-J., Webster-Carrion, A., Gallitto, M., Szalontay, L., Pavisic, J., Tan, Y., Deoli, N., Garty, G., Garvin, J. H., Canoll, P., Vanpouille-Box, C. I., Rabadan, R., Wu, C.-C., & Gartrell, R. D. (2024). RADT-09. IMMUNE RESPONSE IN DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING FLASH OR CONVENTIONAL RADIATION. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.769

Kenkre, R., Chapman, O., Luebeck, J., Bafna, V., Wechsler-Reya, R. J., Mesirov, J., & Chavez, L. (2024). STEM-07. CONSERVATION AND FAITHFUL REPRESENTATION OF CIRCULAR EXTRACHROMOSOMAL DNA IN ORTHOTOPIC PATIENT-DERIVED MEDULLOBLASTOMA XENOGRAFTS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.778

Szalontay, L., CreveCoeur, T., Neira, J., Englander, Z., Spinazzi, E., Canoll, P., Garvin, J., Fino, J., Zamoryakhin, D., Maddocks, A., Feldstein, N., Bruce, J., Wu, C.-C., & Zacharoulis, S. (2024). SURG-07. A PHASE I STUDY EXAMINING THE FEASIBILITY OF INTERMITTENT CONVECTION-ENHANCED DELIVERY (CED) OF MTX110 FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.648

Shatara, M., Paul, M. R., Long-Boyle, J. R., Meyer, A., Raber, S., Yeh-Nayre, L., Jalkanen, A., Kilburn, L. B., Packer, R. J., Elster, J. D., Reddy, A. T., Koschmann, C., Kraya, A., Resnick, A. C., Prados, M., Kline, C., Mueller, S., Wechsler-Reya, R. J., & Rubin, J. B. (2024). TRLS-04. EARLY INSIGHTS FROM PNOC027: PERSONALIZED TREATMENT APPROACHES BASED ON REAL-TIME DRUG SCREENING AND GENOMIC TESTING IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RECURRENT MEDULLOBLASTOMA. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.157

Kline, C., Crawford, J. R., Reddy, A. T., Gerber, N., Stucklin, A. G., Kilburn, L., Packer, R., Margol, A., Crotty, E., Sayour, E., Franson, A., Phillips, J., Singh, S., Hamanishi, E., Lee, C., Bhatia, A., George, E., Rauschecker, A., Molinaro, A., … Mueller, S. (2024). TRLS-07. PNOC016: INTRATUMORAL PHARMACOKINETICS AND PHARMACODYNAMIC (PK/PD) RESULTS FROM A TARGET VALIDATION STUDY OF A NOVEL PAN-HDAC AND PI3K INHIBITOR, FIMEPINOSTAT, IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG), RECURRENT MEDULLOBLASTOMA (MB), AND RECURRENT HIGH-GRADE GLIOMA (HGG). Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.160

Crawford, J. R., Lo, Y. Y., Pagadala, M. S., Chapman, O. S., Sridhar, S., Juarez, E. F., Tzaridis, T., Chau, L. Q., Wang, J., Eisemann, T., Masihi, M. B., Chambers, K. R., Dixit, D., Koubourli, D., Larson, J. D., Guidugli, L., Hammer, M., Wong, T., Abdullaev, Z., … Wechsler-Reya, R. J. (2024). TRLS-13. MULTI-OMICS AND FUNCTIONAL PRECISION MEDICINE FOR NEWLY DIAGNOSED AND RECURRENT PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.166

Prince, E. W., Apps, J. R., Jeang, J., Chee, K., Medlin, S., Jackson, E. M., Dudley, R., Limbrick, D., Naftel, R., Johnston, J., Feldstein, N., Prolo, L. M., Ginn, K., Niazi, T., Smith, A., Kilburn, L., Chern, J., Leonard, J., Lam, S., … Hankinson, T. C. (2024). Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis. Neuro-Oncology, 26(6), 1109–1123. https://doi.org/10.1093/neuonc/noae015

Arrillaga-Romany, I., Lassman, A., McGovern, S. L., Mueller, S., Nabors, B., van den Bent, M., Vogelbaum, M. A., Allen, J. E., Melemed, A. S., Tarapore, R. S., Wen, P. Y., & Cloughesy, T. (2024). ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-Oncology, 26(Supplement_2), S173–S181. https://doi.org/10.1093/neuonc/noae031

Gallitto, M., Pan, P. C., Chan, M. D., Milano, M. T., & Wang, T. J. C. (2024). The role of radiotherapy in immunotherapy strategies in the central nervous system. Neuro-Oncology, 26(Supplement_1), S66–S75. https://doi.org/10.1093/neuonc/noad184

Avila, E. K., Tobochnik, S., Inati, S. K., Koekkoek, J. A. F., McKhann, G. M., Riviello, J. J., Rudà, R., Schiff, D., Tatum, W. O., Templer, J. W., Weller, M., & Wen, P. Y. (2023). Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management. Neuro-Oncology, 26(1), 7–24. https://doi.org/10.1093/neuonc/noad154

Mrugala, M. M., Shi, W., Iwamoto, F. M., Heidemann, M., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2023). LONG-TERM POST-MARKETING SURVEILLANCE DATA FROM ELDERLY PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY. Neuro-Oncology, 25(Supplement_3), iii2–iii2. https://doi.org/10.1093/neuonc/noad147.007

Ellingson, B. M., Wen, P. Y., Chang, S. M., van den Bent, M., Vogelbaum, M. A., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A. B., Gilbert, M. R., de Groot, J. F., Weller, M., Galanis, E., & Cloughesy, T. F. (2023). Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology, 25(6), 1017–1028. https://doi.org/10.1093/neuonc/noad002

Laternser, S., Petrovic, A., Eze, A., Dettwiler, S., Prutek, F., Contini, P. A., Morinigo, D., Bornhorst, M., Rushing, E. J., McDonough, E., Surrette, C., Ginty, F., Minnis, H., Gartrell, R., Müller, S., Packer, R., & Nazarian, J. (2023). DIPG-25. MAPPING TUMOR MICROENVIRONMENT USING EMERGING TECHNOLOGIES FOR PEDIATRIC BRAIN CANCERS. Neuro-Oncology, 25(Supplement_1), i18–i18. https://doi.org/10.1093/neuonc/noad073.072

Fernández, E. C., Wang, J., Zhang, X., Wei, H.-J., Minns, H., Griffin, A., Obradovic, A., Vlahos, L., Martins, T., Becker, P., Crawford, J., Gartrell, R., Szalontay, L., Zacharoulis, S., Zhang, Z., Wechsler-Reya, R., Wu, C.-C., Califano, A., & Pavisic, J. (2023). DIPG-49. A SYSTEMS BIOLOGY APPROACH TO DEFINING AND TARGETING CELL STATE-SPECIFIC MASTER REGULATOR DEPENDENCIES IN DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 25(Supplement_1), i24–i24. https://doi.org/10.1093/neuonc/noad073.096

Ramirez, A., Jonokuchi, A., Hijiya, N., Gomes, W., Wesley, S., & Kaur, G. (2023). IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA. Neuro-Oncology, 25(Supplement_1), i53–i53. https://doi.org/10.1093/neuonc/noad073.206

Hill, K., Giantini-Larsen, A., Hickman, R. A., Holle, B., Alano, T., Doe-Tetteh, S., Bouvier, N., Li, S., Stockfisch, E., Huereca, C., DiNapoli, S., Hertz, C. A., Lee, A., Szalontay, L., Li, B. K., Riviere-Cazaux, C., Burns, T. C., Haque, S., Bale, T., … Miller, A. (2023). METB-05. NON-INVASIVE DIAGNOSIS OF BRAINSTEM GLIOMAS IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS THROUGH CEREBROSPINAL FLUID CELL-FREE DNA SEQUENCING. Neuro-Oncology, 25(Supplement_1), i31–i31. https://doi.org/10.1093/neuonc/noad073.122

Kokossis, D., Wei, H.-J., Gallitto, M., Yoh, N., McQuillan, N., Tazhibi, M., Berg, X., Zhang, X., Szalontay, L., Gartrell, R. D., Pavisic, J., Zhang, Z., Molotkov, A., Mintz, A., Konofagou, E. E., & Wu, C.-C. (2023). SURG-06. ENHANCED DELIVERY OF ANTI-PD1 FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA USING FOCUSED ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER OPENING. Neuro-Oncology, 25(Supplement_1), i73–i73. https://doi.org/10.1093/neuonc/noad073.282

Mrugala, M. M., Shi, W., Iwamoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2023). TRLS-07. GLOBAL POST-MARKETING SURVEILLANCE DATA FROM PEDIATRIC AND ADULT PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY BETWEEN 2011–2022. Neuro-Oncology, 25(Supplement_1), i80–i80. https://doi.org/10.1093/neuonc/noad073.310

Kumthekar, P. U., Avram, M. J., Lassman, A. B., Lin, N. U., Lee, E., Grimm, S. A., Schwartz, M., Bell Burdett, K. L., Lukas, R. V., Dixit, K., Perron, I., Zhang, H., Gradishar, W. J., Pentsova, E. I., Jeyapalan, S., Groves, M. D., Melisko, M., & Raizer, J. J. (2022). A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro-Oncology, 25(3), 557–565. https://doi.org/10.1093/neuonc/noac195

Lassman, A. B., Pugh, S. L., Wang, T. J. C., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., Moazami, G., Macsai, M. S., Gilbert, M. R., Bain, E. E., Blot, V., Ansell, P. J., Samanta, S., Kundu, M. G., Armstrong, T. S., … Mehta, M. P. (2022). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 25(2), 339–350. https://doi.org/10.1093/neuonc/noac173

Rudà, R., Capper, D., Waldman, A. D., Pallud, J., Minniti, G., Kaley, T. J., Bouffet, E., Tabatabai, G., Aronica, E., Jakola, A. S., Pfister, S. M., Schiff, D., Lassman, A. B., Solomon, D. A., Soffietti, R., Weller, M., Preusser, M., Idbaih, A., Wen, P. Y., & van den Bent, M. J. (2022). EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro-Oncology, 24(12), 2015–2034. https://doi.org/10.1093/neuonc/noac188

Pan, P., Haggiagi, A., & Iwamoto, F. (2022). BIOM-12. PROLONGED RESPONSE TO THIRD-LINE TREATMENT WITH COMBINATION CCNU/TMZ IN AN MGMT METHYLATED IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii6–vii6. https://doi.org/10.1093/neuonc/noac209.022

Wen, P. Y., Reardon, D. A., Forst, D., Lee, E., Daoud, T., Berthoud, T., Soare, C., Diaz-Mitoma, F., Anderson, D. E., Lassman, A., & Iwamoto, F. (2022). CTIM-14. COMPREHENSIVE BIOMARKER ANALYSIS OF RESPONDERS AND NON-RESPONDERS IN A PHASE IIA TRIAL OF A CMV VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901). Neuro-Oncology, 24(Supplement_7), vii62–vii62. https://doi.org/10.1093/neuonc/noac209.246

Iwamoto, F., Tanguturi, S., Desai, A., Nayak, L., Uhlmann, E., Wang, T., Lustig, R., Hertan, L., Bagley, S., Hayden, J., Laforest-Roys, C., Muzikansky, A., McCluskey, C., Chukwueke, U., McFaline-Figueroa, J. R., Lee, E., Wen, P. Y., & Reardon, D. (2022). CTIM-18. PHASE 2 STUDY OF PD-1 BLOCKADE WITH PEMBROLIZUMAB PLUS RE-IRRADIATION FOR RECURRENT GLIOBLASTOMA (RGBM) (NCT03661723). Neuro-Oncology, 24(Supplement_7), vii63–vii64. https://doi.org/10.1093/neuonc/noac209.250

Bagley, S., Polley, M.-Y., Kotecha, R., Brem, S., Tolakanahalli, R., Iwamoto, F., Gilbert, M., Won, M., & Mehta, M. (2022). CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS. Neuro-Oncology, 24(Supplement_7), vii64–vii64. https://doi.org/10.1093/neuonc/noac209.253

Liau, L. M., Ashkan, K., Brem, S., Campian, J., Trusheim, J., Iwamoto, F., Tran, D., Anstass, G., Cobbs, C., Heth, J., Salacz, M., D’Andre, S., Aiken, R., Moshel, Y., Nam, J., Pillainayagam, C., Wagner, S., Walter, K., Chaudary, R., … Bosch, M. (2022). CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL. Neuro-Oncology, 24(Supplement_7), vii66–vii66. https://doi.org/10.1093/neuonc/noac209.259

Peereboom, D., Lindsay, R., Badruddoja, M., Nabors, L. B., Kumthekar, P., Lieberman, F., Tran, D., Phuphanich, S., Schiff, D., Sherman, J., Butowski, N., Dunbar, E., Fink, K., Iwamoto, F., Moertel, C., Schulder, M., Walbert, T., Habboubi, N., Grzegorzewski, K., … Reardon, D. A. (2022). CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL. Neuro-Oncology, 24(Supplement_7), vii67–vii67. https://doi.org/10.1093/neuonc/noac209.261

Iwamoto, F., Polley, M.-Y., Shaw, E., Buckner, J., Barger, G., Coons, S., Ricci, P., Gilbert, M., Brown, P., Stelzer, K., Rogers, C. L., Suh, J., Schultz, C., Howard, S., Fisher, B., Kim, M., Huang, J., Haddock, M., Won, M., & Mehta, M. (2022). CTNI-16. NRG-RTOG 9802 OBSERVATION ARM - LONG TERM RESULT. Neuro-Oncology, 24(Supplement_7), vii73–vii73. https://doi.org/10.1093/neuonc/noac209.282

Buxton, M., Alexander, B., Berry, D., Cavenee, W., Colman, H., de Groot, J., Ellingson, B., Gordon, G., Khasraw, M., Lassman, A., Lee, E., Li, W., Lim, M., Mellinghoff, I., Mikkelsen, T., Nelli, A., Perry, J., Sulman, E., Tanner, K., … Cloughesy, T. (2022). CTNI-38. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii80–vii80. https://doi.org/10.1093/neuonc/noac209.303

Iwamoto, F., Gondi, V., Butowski, N., Falchook, G., Williams, A., Peters, K. B., Evans, J., Lakhani, N., McKean, M., Symeonides, S., Ellingson, B., Rotolo, J., Capiaux, G., Wiegert, E., Michel, R., Kaesshaefer, S., & Bexon, A. (2022). CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology, 24(Supplement_7), vii83–vii83. https://doi.org/10.1093/neuonc/noac209.314

Castro, M., Iwamoto, F., Ahluwalia, M., Usmani, S., Kumar, A., Kapoor, S., Suseela, R. P., Kulkarni, S., Mohanty, J., Shyamasundar, V., Ghosh, A., Prasad, N., Patil, M., Choudhury, S. R., Chauhan, J., Sauban, M., Joseph, V., Kumari, P., Mitra, U., … Basu, S. (2022). EPCO-06. THE IMPACT OF MISMATCH REPAIR DEFICIENCY (MMRD) ON SURVIVAL OF TEMOZOLOMIDE (TMZ)-TREATED PATIENTS WITH MGMT METHYLATED (M-MGMT) GLIOBLASTOMA (GBM): A CELLWORKS COMPUTATIONAL BIOSIMULATION PILOT STUDY. Neuro-Oncology, 24(Supplement_7), vii116–vii117. https://doi.org/10.1093/neuonc/noac209.441

Oh, M., Hasanain, M., Migliozzi, S., Garofano, L., D’Angelo, F., Stefano, A. L. D., Lerond, J., Sarkaria, J., Ceccarelli, M., Sanson, M., Lasorella, A., & Iavarone, A. (2022). EXTH-21. DEVELOPMENT OF THERAPEUTIC STRATEGIES BY PATHWAY-BASED MULTI-OMICS APPROACH AND MASTER KINASE ANALYSIS IN GLIOBLASTOMA MULTIFORME. Neuro-Oncology, 24(Supplement_7), vii214–vii214. https://doi.org/10.1093/neuonc/noac209.820

Mrugala, M., Shi, W., Iwamoto, F., Lukas, R., Palmer, J., Suh, J., & Glas, M. (2022). INNV-07. TUMOR TREATING FIELDS (TTFIELDS; 200 KHZ) POST-MARKETING SAFETY DATA FROM PATIENTS WITH GLIOBLASTOMA TREATED BETWEEN 2011–2022. Neuro-Oncology, 24(Supplement_7), vii142–vii142. https://doi.org/10.1093/neuonc/noac209.547

Pan, P., Joanta-Gomez, A., Yuen, C., Donovan, L., Haggiagi, A., Welch, M., Iwamoto, F., & Lassman, A. (2022). NCOG-24. TIME TO FIRST RECURRENCE AND SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii202–vii202. https://doi.org/10.1093/neuonc/noac209.776

Ellingson, B., Wen, P. Y., Chang, S., van den Bent, M., Vogelbaum, M., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A., Gilbert, M., de Groot, J., Weller, M., Galanis, E., & Cloughesy, T. (2022). NIMG-42. DURABLE OVERALL RESPONSE RATE (ORR) TARGETS FOR RECURRENT GLIOBLASTOMA (RGBM) CLINICAL TRIALS BASED ON THE HISTORIC ASSOCIATION BETWEEN ORR AND MEDIAN OVERALL SURVIVAL (MOS). Neuro-Oncology, 24(Supplement_7), vii172–vii173. https://doi.org/10.1093/neuonc/noac209.660

Yuen, C., Pan, P., Teasley, D., Miller, M., Sun, Y., Canoll, P., Joanta-Gomez, A., Bargo, A., & Iwamoto, F. (2022). PATH-32. CONCORDANCE FOR CDKN2A/B LOSS AND TERT MUTATION IN WHO 2021 CLASSIFICATION GRADE 3 MENINGIOMAS: A RETROSPECTIVE STUDY. Neuro-Oncology, 24(Supplement_7), vii157–vii157. https://doi.org/10.1093/neuonc/noac209.605

Donovan, L., Joanta-Gomez, A., Furnari, J., Mouton, B., & Lassman, A. (2022). QOL-01. RISK FACTORS FOR AND CONSEQUENCES OF PROLONGED DEXAMETHASONE USE IN PATIENTS WITH GLIOBLASTOMA (GBM). Neuro-Oncology, 24(Supplement_7), vii240–vii240. https://doi.org/10.1093/neuonc/noac209.929

Arrillaga-Romany, I., Lassman, A., McGovern, S., Mueller, S., Nabors, L. B., van den Bent, M., Vogelbaum, M., Allen, J. E., Melemed, A., Tarapore, R., Yang, D., Wen, P. Y., & Cloughesy, T. (2022). RTID-01. ONC108: A RANDOMIZED PHASE 3 STUDY OF ONC201 IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA. Neuro-Oncology, 24(Supplement_7), vii249–vii249. https://doi.org/10.1093/neuonc/noac209.961

Minns, H., Padilla, O., Wei, H.-J., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Yeh, R., Zhang, Z., Szalontay, L., Pavisic, J., Garty, G., Garvin, J., Canoll, P., Vanpouille-Box, C., Menon, V., Olah, M., Rabadan, R., Wu, C.-C., & Gartrell, R. (2022). TMIC-68. EVALUATING FLASH AND CONVENTIONAL DOSE-RATE RADIATION AND IMMUNE RESPONSE WITH SINGLE-CELL SEQUENCING IN DIFFUSE MIDLINE GLIOMA (DMG). Neuro-Oncology, 24(Supplement_7), vii286–vii286. https://doi.org/10.1093/neuonc/noac209.1111

Miller, A. M., Szalontay, L., Bouvier, N., Hill, K., Ahmad, H., Rafailov, J., Lee, A. J., Rodriguez-Sanchez, M. I., Yildirim, O., Patel, A., Bale, T. A., Benhamida, J. K., Benayed, R., Arcila, M. E., Donzelli, M., Dunkel, I. J., Gilheeney, S. W., Khakoo, Y., Kramer, K., … Karajannis, M. A. (2022). Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. Neuro-Oncology, 24(10), 1763–1772. https://doi.org/10.1093/neuonc/noac035

Ellingson, B. M., Gerstner, E. R., Lassman, A. B., Chung, C., Colman, H., Cole, P. E., Leung, D., Allen, J. E., Ahluwalia, M. S., Boxerman, J., Brown, M., Goldin, J., Nduom, E., Hassan, I., Gilbert, M. R., Mellinghoff, I. K., Weller, M., Chang, S., Arons, D., … Cloughesy, T. F. (2022). Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 24(8), 1219–1229. https://doi.org/10.1093/neuonc/noac086